Indivior Pharmaceuticals
INDV
103 hedge funds and large institutions have $834M invested in Indivior Pharmaceuticals in 2024 Q3 according to their latest regulatory filings, with 27 funds opening new positions, 28 increasing their positions, 30 reducing their positions, and 22 closing their positions.
23% more call options, than puts
Call options by funds: $2.16M | Put options by funds: $1.75M
23% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 22
6.64% more ownership
Funds ownership: 48.33% → 54.97% (+6.6%)
4% more funds holding
Funds holding: 99 → 103 (+4)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
7% less repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 30
31% less capital invested
Capital invested by funds: $1.22B → $834M (-$383M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
+$59.6M |
| 2 |
Morgan Stanley
New York
|
+$59.4M |
| 3 |
OCM
Oaktree Capital Management
Los Angeles,
California
|
+$58.9M |
| 4 |
MAP
Madison Avenue Partners
New York
|
+$43.8M |
| 5 |
Goldman Sachs
New York
|
+$41.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$76.6M |
| 2 |
SCM
Scopia Capital Management
New York
|
-$54.1M |
| 3 |
Barclays
London,
United Kingdom
|
-$30M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$28.2M |
| 5 |
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
|
-$18.4M |
INDV Hedge Fund Activity: Q3 2024 in Review
103 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Indivior Pharmaceuticals (INDV) for Q3 2024, worth a combined $834M — down 31% from $1.22B a quarter earlier.
Buyers outnumbered sellers: 27 funds opened new INDV positions and 22 closed out — a net gain of 5 holders — while 28 added to existing stakes and 30 trimmed.
The largest buyer was Deerfield Management, opening a new position worth an estimated $59.6M. The largest seller was Fidelity Investments, cutting an estimated $76.6M.
- 103 institutional investors held Indivior Pharmaceuticals (INDV) as of Q3 2024, up from 99 in Q2 2024.
- Funds reported $834M of Indivior Pharmaceuticals stock for Q3 2024, down 31% quarter-over-quarter.
- 27 funds opened new Indivior Pharmaceuticals positions in Q3 2024 and 22 closed out, a net change of +5 holders.
- The largest Indivior Pharmaceuticals buyer in Q3 2024 was Deerfield Management, an estimated $59.6M added.
- The largest Indivior Pharmaceuticals seller in Q3 2024 was Fidelity Investments, an estimated $76.6M sold.
Based on aggregated 13F filings for Q3 2024.